Related Experiment Videos
[Current and future biochemical markers for Gaucher disease].
1Laboratoire de Biochimie Pédiatrique, Hôpital Debrousse, 29, rue Sceur-Bouvier, 69322 Lyon cedex 05, France. roseline.froissart@chu-lyon.fr
La Revue De Medecine Interne
|April 29, 2006
Summary
Biomarkers for Gaucher disease are numerous, but none are perfect. Chitotriosidase and chemokine CCL18 are currently the most useful for tracking enzyme replacement therapy effectiveness.
Area of Science:
- Biochemistry
- Cell Biology
- Immunology
Context:
- Gaucher disease involves complex cellular processes and the secretion of numerous biochemical markers by Gaucher cells.
- Current biomarkers for Gaucher disease lack ideal qualities for comprehensive assessment.
Purpose:
- To review the current landscape of Gaucher cell biomarkers.
- To highlight the utility of chitotriosidase and chemokine CCL18 in monitoring enzyme replacement therapy (ERT).
- To emphasize the need for novel biomarkers for a deeper understanding of Gaucher disease pathophysiology.
Summary:
- While numerous biochemical markers are secreted by Gaucher cells, none fully meet the criteria for an ideal biomarker.
- Chitotriosidase and chemokine CCL18 are identified as the most practical markers for monitoring the efficacy of enzyme replacement therapy in Gaucher disease patients.
- The discovery of new biomarkers is anticipated to significantly advance the understanding of the complex pathophysiology underlying Gaucher disease.
Impact:
- Improved monitoring of enzyme replacement therapy for Gaucher disease.
- Potential for earlier and more accurate diagnosis through novel biomarkers.
- Enhanced understanding of Gaucher disease mechanisms, paving the way for targeted therapeutic strategies.